



stratech.co.uk/signalchem info@stratech.co.uk

2019-nCoV Spike protein S1 (K417N, E484K, N501Y, D614G)

Catalog No: C19S1-G238H

Novel coronavirus SARS-CoV-2 has caused the pandemic of the respiratory diseases (COVID-19) around the world since 2020.

- SARS-CoV-2 (501Y.V2 variant) with mutations K417N, E484K and N501Y in the spike protein severely affected regions of South Africa.
- A combination of E484K, K417N and N501Y results in the highest degree of conformational modifications of receptor binding domain of spike protein when bound to hACE2, compared to either E484K or N501Y alone.
- E484K and N501Y increase affinity of RBD for hACE2 and the charge switch due to E484K leads to the formation of favorable contacts.

Product Features



Purity determined by densitometry



Biologically Active



QA/AC Tested



Strong binding affinity to ACE2

Competitors





Biopharma companies developing anti-SARS cov 2 therapies



Scientists developing diagnostic tests





Biotech companies research A222V neutralization



Universities investigating SARS-COV-2